Eli Lilly has announced a partnership with AI-based biotech Genetic Leap, securing a deal worth up to $409 million in upfront and milestone payments. Genetic Leap specializes in discovering RNA-targeted drugs, using advanced AI technology to explore undruggable targets. Under the deal, Lilly will select high-priority therapeutic targets, while Genetic Leap focuses on developing oligonucleotide drugs to treat them.
This agreement makes Genetic Leap part of a growing group of biotech firms redefining the potential for RNA-based therapies. Historically, RNA was seen as difficult to target with small molecules due to its molecular structure. However, the landscape is changing, with biotechs like Arrakis Therapeutics and now Genetic Leap, leveraging AI to overcome these challenges.
Lilly’s decision to partner with Genetic Leap follows its broader commitment to RNA research, signaled by the recent opening of a $700 million nucleic acid R&D center in Boston. The company’s focus is on improving the delivery of RNA and DNA medicines to address difficult-to-treat diseases such as neurodegeneration, diabetes, and obesity.
Although the upfront payment size is undisclosed, the total value of the deal could reach $409 million if milestones are met. This collaboration continues Lilly’s strategic focus on using AI and advanced technologies to unlock new therapeutic options in critical medical fields.
Click here to read the original news story.